%0 Journal Article
%T Switching from infliximab to biosimilar in inflammatory bowel
disease: overview of the literature and perspective
%A Anna F¨˘bi¨˘n
%A Tam¨˘s Moln¨˘r
%A ¨˘gnes Milassin
%J Archive of "Therapeutic Advances in Gastroenterology".
%D 2019
%R 10.1177/1756284819842748
%X Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the same indications as the reference product; however, the approval was based on extrapolated data from rheumatoid arthritis and ankylosing spondylitis. Our aim was to review clinical studies about switching from originator infliximab (IFX-O) to biosimilar infliximab (IXF-B) in IBD, focusing on recently published data and the future of biosimilars
%K biosimilar
%K inflammatory bowel disease
%K infliximab
%K switching
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469269/